Showing 1911-1920 of 2526 results for "".
- TearLab Announces Corporate Name Change to Trukera Medical; Targets Corneal Healthhttps://modernod.com/news/tearlab-announces-corporate-name-change-to-trukera-medical-targets-corneal-health/2481067/TearLab announced that it will be expanding its position in corneal health under the new name Trukera Medical. The rebranding reflects the company’s vision and future growth strategy targeting a broader set of unmet needs across corneal health. “We continue to rema
- Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments Intraocular Dyeshttps://modernod.com/news/bausch-lomb-named-exclusive-global-distributor-of-alfa-instruments-intraocular-dyes/2481060/Bausch + Lomb and Alfa Instruments announced that the companies have entered into an exclusive distribution agreement under which Bausch + Lomb will distribute and commercialize Alfa Instruments' line of surgical intraocular dyes—Vitreocare—globally with the exception of Italy, wh
- Bausch Health Continuing Process Toward Separating Bausch + Lombhttps://modernod.com/news/bausch-health-continuing-process-toward-separating-bausch-lomb/2481048/Bausch Health Companies announced it is moving toward separating Bausch + Lomb after transferring common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb to an existing wholly-owned unrestricted subsidiary of the company.
- eSight and Marathon Medical Partner to Provide Sight Medical Devices to the US Department of Veterans Affairshttps://modernod.com/news/esight-and-marathon-medical-partner-to-provide-sight-medical-devices-to-the-us-department-of-veterans-affairs/2481043/Vision-enhancement platform eSight and Marathon Medical Corp., a SDVOSB (Service-Disabled Veteran Owned Small Business) certified distributor to veteran medical facilities across the United States, announced that the’ve partnered to provide eSight 4 assistive eyewear medical devices to
- BVI Installs First Beyeonics One Systemhttps://modernod.com/news/bvi-installs-first-beyeonics-one-system/2481035/BVI announced that the first Beyeonics One System has been installed at Holzman Solomon Vision Partners, in McClean, Virginia. On August 17, Jonathon Solomon, MD, was the first US surgeon to offer ophthalmic surgery with the Beyeonics One platform in private practice. Under th
- Oyster Point's Tyrvaya To Be Covered By the Largest Medicare Pharmacy Benefit Managerhttps://modernod.com/news/oyster-point-pharma-announces-tyrvana-to-be-covered-by-the-largest-medicare-pharmacy-benefit-manager/2481032/Oyster Point Pharma announced that the largest Medicare Pharmacy Benefit Manager in the United States will add Tyrvaya Nasal Spray on its Medicare Part D formularies, effective September 1, 2022. “We are excited to announce this important milestone which will further expand p
- Glaukos Receives FDA 510(k) Clearance of the iStent Infinitehttps://modernod.com/news/glaukos-receives-fda-510k-clearance-for-the-istent-infinite/2481013/Glaukos announced that it has received 510(k) clearance from the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is indicated for use in a standalone procedure to reduce elevated IOP in patients with primary open-angle glaucoma uncontrolled
- Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseaseshttps://modernod.com/news/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases/2480977/Avista Therapeutics, which recently launched as a spinout of the University of Pittsburgh Medical Center (UPMC), announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply Avista’s single-cell adeno-associated
- Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimurahttps://modernod.com/news/iveric-bio-and-delsitech-enter-exclusive-agreement-for-development-of-sustained-release-zimura/2480948/Iveric bio and DelSiTech announced an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. Under the terms of the l
- Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabeticshttps://modernod.com/news/ocuphire-granted-new-us-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diabetics/2480941/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330, for diabetic eye disease. In addition, a new publication supporting the nov